Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cytarabine + Mitoxantrone + Tretinoin
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous (iv), Intrathecal (it), Oral
01
Overview
**Cytarabine + Mitoxantrone + Tretinoin** is a combination used in the treatment of acute promyelocytic leukemia (APL). - **Cytarabine** is a nucleoside analog that interferes with DNA synthesis, thereby inhibiting cancer cell growth. It is used primarily in the treatment of various forms of leukemia. - **Mitoxantrone** is an anthracenedione antineoplastic agent that intercalates DNA strands, thereby inhibiting DNA topoisomerase II, which is crucial for DNA replication and transcription. - **Tretinoin** (all-trans retinoic acid, ATRA) is a retinoid that induces differentiation of immature blood cells into mature cells, making it effective in treating APL. It specifically targets the PML-RARα fusion protein characteristic of APL. The combination is often used in consolidation phases of APL treatment to ensure complete remission.
- Other names
- Combination of Cytarabine, Mitoxantrone, and Tretinoin
02
Targets
RARA (Retinoic acid receptor alpha)DNARARG (Retinoic acid receptor gamma)RXRA (Retinoid X receptor alpha)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on Cytarabine + Mitoxantrone + Tretinoin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cytarabine + Mitoxantrone + Tretinoin.